No Prescription |
 |
 | ||
|
Galvus Generic Vidagliptin |
|
| ||
No Prescription » Prescription Drugs 8 » Galvus Generic Vidagliptin Vildagliptin treats type 2 diabetes.People with type 2 diabetes have too much glucose (sugar) in their blood because their body does not produce enough insulin or their insulin has become less effective (called insulin resistance).Having high blood glucose levels increases your risk of developing the long-term complications of diabetes.These complications are serious. People with diabetes may develop heart disease kidney disease eye disease pain or loss of feeling and poor circulation in the feet and problems with sexual function. Vildagliptin treats type 2 diabetes by controlling blood glucose levels. Buy Galvus Generic Vidagliptin and other Prescription Drugs 8 products online at Medstore. Buy Online at Medstore - Click Here!
About Galvus Generic Vidagliptin: Product Type: Prescription Drugs 8 Galvus (Generic Vidagliptin) Galvus (Generic Vidagliptin) Generic Vidagliptin 50mg 28 Tablets 3 x 28 Tablets 6 x 28 Tablets Generic Vidagliptin Galvus
View more Prescription Drugs 8 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
